Proteomics

Dataset Information

0

Tasmanian Devil Facial Tumour Disease - Imiquimod treatment of DFT1 cells


ABSTRACT: A Tasmanian Devil Facial Tumour Disease (DFTD) tumor cell line was treated with the drug Imiquimod

INSTRUMENT(S): LTQ Orbitrap

ORGANISM(S): Sarcophilus Harrisii

TISSUE(S): Cell Culture

SUBMITTER: Richard Wilson  

LAB HEAD: Richard Wilson

PROVIDER: PXD007135 | Pride | 2018-04-12

REPOSITORIES: Pride

altmetric image

Publications

Transcriptome and proteome profiling reveals stress-induced expression signatures of imiquimod-treated Tasmanian devil facial tumor disease (DFTD) cells.

Patchett Amanda L AL   Wilson Richard R   Charlesworth Jac C JC   Corcoran Lynn M LM   Papenfuss Anthony T AT   Lyons Bruce A BA   Woods Gregory M GM   Tovar Cesar C  

Oncotarget 20180323 22


As a topical cancer immunotherapy, the toll-like receptor 7 ligand imiquimod activates tumor regression via stimulation of immune cell infiltration and cytotoxic responses. Imiquimod also exerts direct pro-apoptotic effects on tumor cells <i>in vitro</i>, but a role for these effects in imiquimod-induced tumor regression remains undefined. We previously demonstrated that cell lines derived from devil facial tumor disease (DFTD), a transmissible cancer threatening the survival of the Tasmanian de  ...[more]

Similar Datasets

2021-09-09 | PXD021784 | Pride
2010-01-01 | E-GEOD-18352 | biostudies-arrayexpress
2021-02-08 | PXD020614 | Pride
2019-01-14 | GSE108107 | GEO
2023-04-27 | PXD020766 | Pride
2019-01-18 | PXD009283 | Pride
2019-01-14 | GSE108160 | GEO
2010-01-01 | GSE18352 | GEO
2022-03-14 | PXD021480 | Pride
2019-08-06 | PXD011209 | Pride